Novozymes A/S (OTCMKTS:NVZMF – Get Rating) is one of 376 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Novozymes A/S to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Novozymes A/S and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Novozymes A/S | 0 | 0 | 0 | 0 | N/A |
| Novozymes A/S Competitors | 494 | 1603 | 4626 | 55 | 2.63 |
As a group, “Biotechnology” companies have a potential upside of 80.95%. Given Novozymes A/S’s rivals higher possible upside, analysts plainly believe Novozymes A/S has less favorable growth aspects than its rivals.
Valuation and Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Novozymes A/S | N/A | N/A | 5.97 |
| Novozymes A/S Competitors | $118.59 million | -$13.54 million | 22.21 |
Novozymes A/S’s rivals have higher revenue, but lower earnings than Novozymes A/S. Novozymes A/S is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Novozymes A/S and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Novozymes A/S | N/A | N/A | N/A |
| Novozymes A/S Competitors | -636.54% | -58.71% | -17.44% |
Dividends
Novozymes A/S pays an annual dividend of $1.80 per share and has a dividend yield of 3.8%. Novozymes A/S pays out 22.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 2.8% and pay out 1,850.5% of their earnings in the form of a dividend. Novozymes A/S is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
Institutional and Insider Ownership
20.4% of Novozymes A/S shares are owned by institutional investors. Comparatively, 25.9% of shares of all “Biotechnology” companies are owned by institutional investors. 25.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
About Novozymes A/S
Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
